LLY

Eli Lilly

research_scan theme='longevity-aging'; value_chain_position='Cardio-metabolic pharma / disease displacement'; Cleanest single-name expression of morbidity-compression demand from the 65+ wave. Cash-generative, pricing-power intact, real-asset-earnings franchise. Complements C-10/C-16 (demographic tailwind for age-linked pharma) without triggering C-01/C-08 avoids. Watch: Medicare Part D negotiation risk on GLP-1 class post-2026.